Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0

被引：1
|
作者：
Vairetti, Mariapia [1 ]
Colucci, Giuseppe [2 ]
Ferrigno, Andrea [1 ]
机构：
[1] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy
[2] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Div Gastroenterol & Hepatol, I-20122 Milan, Italy
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 14期
关键词：
STEATOSIS; MODEL; DIET; ACID;
D O I：
10.3390/ijms23147894
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Innovative Molecular Targets and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 3.0
    Vairetti, Mariapia
    Colucci, Giuseppe
    Ferrigno, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [2] Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH)
    Ota, Tsuguhito
    CAROTENOIDS: BIOSYNTHETIC AND BIOFUNCTIONAL APPROACHES, 2021, 1261 : 223 - 229
  • [3] Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
    Duarte, Sebastiao M. B.
    Stefano, Jose Tadeu
    Oliveira, Claudia P.
    ANNALS OF HEPATOLOGY, 2019, 18 (03) : 416 - 421
  • [4] Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
    Drescher, Hannah K.
    Weiskirchen, Sabine
    Weiskirchen, Ralf
    CELLS, 2019, 8 (08)
  • [5] Predictive Factors for Nonalcoholic Steatohepatitis (NASH) in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
    Fierbinteanu-Braticevici, Carmen
    Baicus, Cristian
    Tribus, Laura
    Papacocea, Raluca
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2011, 20 (02) : 153 - 159
  • [6] Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in Patients with Morbid Obesity
    Manno, Emilio
    OBESITY SURGERY, 2010, 20 (06) : 811 - 811
  • [7] Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)
    Gerhardt, Florian
    Petroff, David
    Blank, Valentin
    Boehlig, Albrecht
    van Boemmel, Florian
    Wittekind, Christian
    Berg, Thomas
    Karlas, Thomas
    Wiegand, Johannes
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 706 - 711
  • [8] Saroglitazar Shows Therapeutic Benefits in Mouse Model of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
    Jain, Mukul R.
    Giri, Suresh R.
    Bhoi, Bibhuti
    Trivedi, Chitrang
    Ranvir, Ramchandra
    Kadam, Shekhar
    Swain, Prabodha
    Patel, Pankaj R.
    DIABETES, 2015, 64 : A503 - A503
  • [9] Vitamin D deficiency and development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
    Bril, Fernando
    Lomonaco, Romina
    Orsak, Beverly
    Ortiz-Lopez, Carolina
    Biernacki, Diane
    Klaczak, Ashley
    Chang, Zhi
    Hardies, Jean
    Cusi, Kenneth
    HEPATOLOGY, 2013, 58 : 522A - 522A
  • [10] Variants of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with rapidly progressive course
    Tan, V.
    Merriman, R.
    Ferrell, L.
    LABORATORY INVESTIGATION, 2008, 88 : 317A - 317A
12345